Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...
Zacks Investment Research on MSN
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase III VANQUISH-1 study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback